Loading
MMAF is a charged cousin of MMAE that cannot cross membranes, so it kills only the targeted cell and spares neighbours. Eye side effects are characteristic.
MMAF, monomethyl auristatin F, is a charged cousin of MMAE that cannot cross cell membranes, so it kills only the cell the antibody targets and spares its neighbours. The charge comes from a C-terminal phenylalanine, which stops the free payload leaving the cell. Used with non-cleavable linkers, in the form known as mafodotin, it produces little Bystander effect (ADC) and less neuropathy than MMAE, but it has a distinctive corneal toxicity seen with Belantamab mafodotin. The payload belongs to the Antibody-drug conjugate (ADC) technology and to the terms Payload (ADC) and Tubulin inhibitor payloads, and it is referenced by the linker term Maleimidocaproyl (mc), non-cleavable, which is its usual partner.
Ball-and-stick model from PubChem 2D record (no 3D conformer available). PubChem record
Showing the molecule this term concerns: Belantamab mafodotin.
Shares Bystander effect (ADC), Tubulin inhibitor payloads, Payload (ADC), Antibody-drug conjugate (ADC).
Shares Bystander effect (ADC), Tubulin inhibitor payloads, Payload (ADC), Antibody-drug conjugate (ADC).
Shares Bystander effect (ADC), Payload (ADC), Antibody-drug conjugate (ADC).
Shares Bystander effect (ADC), Tubulin inhibitor payloads, Payload (ADC), Antibody-drug conjugate (ADC).
Shares Tubulin inhibitor payloads, Belantamab mafodotin, Antibody-drug conjugate (ADC).
Shares Bystander effect (ADC), Payload (ADC), Antibody-drug conjugate (ADC).